|Bid||16.13 x 1200|
|Ask||16.22 x 800|
|Day's Range||15.31 - 16.65|
|52 Week Range||14.75 - 19.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.41|
Internet services company Cloudflare was set to begin trading Friday, after raising $525 million with an initial public offering that priced Thursday. Cloudflare offered 35 million shares.
SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing ...
South San Francisco-based Satsuma Pharmaceuticals, Inc. has filed for an IPO of 5 million shares of its common stock. The company said in the filing that some of its existing investors affiliated with some of its directors have expressed interest in buying about $25 million in shares. Founded in June 2016, Satsuma is a clinical-stage biopharma company developing a novel therapeutic product for the acute treatment of migraines.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of up to 5,000,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Satsuma. In addition, Satsuma expects to grant the underwriters for the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.